ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that, pursuant to the company's consent solicitation dated July 11, 2023, holders of 48.5% of
Full Story >>
Vote
+27